NOACs slow cognitive decline in Alzheimer’s patients with atrial fibrillation
A Karolinska study linked NOAC use to about 0.2 points less annual MMSE decline than warfarin or no anticoagulant.
OriginalSourceScienceDailyUnited StatesLeanCenterCredibilityPublished09:48 UTCRatings: AllSides, MBFCSourceScienceDailyUnited StatesLeanCenterCredibilityPublished09:48 UTCRatings: AllSides, MBFC
“These blood thinners may have an unexpected benefit for Alzheimer’s patients”
NOACs slow cognitive decline in Alzheimer’s patients with atrial fibrillation
Key points
- Karolinska Institutet study analyzed 7,308 patients with atrial fibrillation and Alzheimer’s.
- Participants were grouped to NOACs, warfarin, or no anticoagulant treatment.
- NOACs slowed MMSE decline by about 0.2 points per year versus others.
- NOACs also linked to lower risks of death, stroke, clots, and fractures.
- Study notes observational design and cannot prove causation; potential confounders exist.
How it got here
ScienceDaily publishes the article.
concise reads it.
The Brief ranks it 10th.
10 10 NOACs slow cognitive decline in Alzheimer’s patients with atrial fibrillation
A Karolinska study linked NOAC use to about 0.2 points less annual MMSE decline than warfarin or no anticoagulant.